Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome

European Journal of Haematology

Volumn 76, Issue 6, 2006, Pages 465-472

  Kojima, Yasushi ^a   Tsurumi, Hisashi ^a   Goto, Naoe ^a   Shimizu, Masahito ^a   Kasahara, Senji ^a   Yamada, Toshiki ^a   Kanemura, Nobuhiro ^a   Hara, Takeshi ^b   Sawada, Michio ^b   Saio, Masanao ^a   Yamada, Tetsuya ^c   Takahashi, Takeshi ^c   Tomita, Eiichi ^c   Takami, Tsuyoshi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c Gifu Municipal Hospital   (Japan)

Author keywords

Diffuse large B cell lymphoma; Fas; Fas ligand; Germinal center type; Prognostic factor

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; PIRARUBICIN; PREDNISOLONE; PROTEIN BCL 6; PROTEIN MUM1; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BINDING SITE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; FEMALE; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOXORUBICIN; FAS LIGAND PROTEIN; FEMALE; FOLLOW-UP STUDIES; GERMINAL CENTER; HUMANS; INTERFERON REGULATORY FACTORS; L-LACTATE DEHYDROGENASE; LIFE TABLES; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PREDNISOLONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTORS; TUMOR STEM CELLS; VINCRISTINE;

EID: 33646525992     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00631.x     Document Type: Article

References (48)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med 1993 329 987 994
2. A lizadeh AA E isen MB D avis RE et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 2000 403 503 511
3. H ans CP W eisenburger DD G reiner TC et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 2004 103 275 282
4. S hipp MA R oss KN T amayo P et al Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 2002 8 68 74
5. R osenwald A W right G C han WC et al Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 2002 346 1937 1947
6. L ossos IS C zerwinski DK A lizadeh AA W echser MA T ibshirani R B otstein D L evy R Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes N Engl J Med 2004 350 1828 1837
7. T akahashi T T anaka M I nazawa J A be T S uda T N agata S Human Fas ligand: gene structure, chromosomal location and species specificity Int Immunol 1994 6 1567 1574
8. K ondo E Y oshino T Y amadori I M atsuo Y K awasaki N M inowada J A kagi T Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas Am J Pathol 1994 145 330 337
9. N guyen PL H arris NL R itz J R obertson MJ Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease Am J Pathol 1996 148 847 853 Erratum in Am J Pathol 1996 149 346
10. S aez AI S aez AJ A rtiga MJ et al Building an outcome predictor model for diffuse large B-cell lymphoma Am J Pathol 2004 164 613 622
11. P lumas J J acob MC C haperot L M olens JP S otto JJ B ensa JC Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis Blood 1998 91 2875 2885
12. J affe ES H arris NL S tein H V ardiman JW eds World Health Organization Classification of Tumors, Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues Lyon IARC Press 2001 109 236
13. C arbone PP K aplan HS M usshoff K S mithers DW T ubiana M Report of the committee on Hodgkin's disease staging classification Cancer Res 1971 31 1860 1861
14. T surumi H Y amada T S awada M et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study J Cancer Res Clin Oncol 2004 130 107 113
15. C hang CC M c C lintock S C leveland RP T rzpuc T V esole DH L ogan B K ajdacsy -B alla A P erkins SL Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma Am J Surg Pathol 2004 28 464 470
16. K iyokawa N K okai Y I shimoto K F ujita H F ujimoto J H ata JI Characterization of the common acute lymphoblastic leukaemia antigen (CD10) as an activation molecule on mature human B cells Clin Exp Immunol 1990 79 322 327
17. C olomo L L opez -G uillermo A P erales M R ives S M artinez A B osch F C olomer D F alini B M ontserrat E C ampo E Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma Blood 2003 101 78 84
18. L inderoth J J erkeman M C avallin -S tahl E K valoy S T orlakovic E Nordic Lymphoma Group Study Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study Clin Cancer Res 2003 9 722 728
19. O hshima K K awasaki C M uta H M uta K D eyev V H araoka S S uzumiya J P odack ER K ikuchi M CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis Histopathology 2001 39 156 162
20. U herova P R oss CW S chnitzer B S ingleton TP F inn WG The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma Am J Clin Pathol 2001 115 582 588
21. F lenghi L Y e BH F izzotti M B igerna B C attoretti G V enturi S P acini R P ileri S L o C oco F P escarmona E A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells Am J Pathol 1995 147 405 411
22. O nizuka T M oriyama M Y amochi T K uroda T K azama A K anazawa N S ato K K ato T O ta H M ori S BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts Blood 1995 86 28 37
23. C attoretti G C hang CC C echova K Z hang J Y e BH F alini B L ouie DC O ffit K C haganti RS D alla -F avera R BCL-6 protein is expressed in germinal-center B cells Blood 1995 86 45 53
24. M ittrucker HW M atsuyama T G rossman A K undig TM P otter J S hahinian A W akeham A P atterson B O hashi PS M ak TW Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function Science 1997 275 540 543
25. L ossos IS J ones CD W arnke R N atkunam Y K aizer H Z ehnder JL T ibshirani R L evy R Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma Blood 2001 98 945 951
26. N agata S G olstein P The Fas death factor Science 1995 267 1449 1456
27. S uda T T akahashi T G olstein P N agata S Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family Cell 1993 75 1169 1178
28. S traus SE J affe ES P uck JM et al The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis Blood 2001 98 194 200
29. H olzelova E V onarbourg C S tolzenberg MC et al Autoimmune lymphoproliferative syndrome with somatic Fas mutations N Engl J Med 2004 351 1409 1418
30. M ysler E B ini P D rappa J R amos P F riedman SM K rammer PH E lkon KB The apoptosis-1/Fas protein in human systemic lupus erythematosus J Clin Invest 1994 93 1029 1034
31. I chikawa Y A rimori K Y oshida M H oriki T H oshina Y M orita K U chiyama M S himizu H M oriuchi J T akaya M Abnormal expression of apoptosis-related antigens, Fas and bcl-2, on circulating T-lymphocyte subsets in primary Sjogren's syndrome Clin Exp Rheumatol 1995 13 307 313
32. G riffith TS B runner T F letcher SM G reen DR F erguson TA Fas ligand-induced apoptosis as a mechanism of immune privilege Science 1995 270 1189 1192
33. B ennett MW O 'connell J O 'sullivan GC R oche D B rady C K elly J C ollins JK S hanahan F Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer Gut 1999 44 156 162
34. S heehan KM O'D onovan DG F itzmaurice G O 'Grady A O'D onoghue DP S heahan K B yrne MF C onroy RM K ay EW M urray FE Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer Eur J Gastroenterol Hepatol 2003 15 375 380
35. B ennett MW O'C onnell J O'S ullivan GC B rady C R oche D C ollins JK S hanahan F The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma J Immunol 1998 160 5669 5675
36. I to Y M onden M T akeda T et al The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma Br J Cancer 2000 82 1211 1217
37. K amihira S Y amada Y T omonaga M S ugahara K T suruda K Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis Br J Haematol 1999 107 851 860
38. N i X H azarika P Z hang C T alpur R D uvic M Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape Clin Cancer Res 2001 7 2682 2692
39. S hima Y N ishimoto N O gata A F ujii Y Y oshizaki K K ishimoto T Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis Blood 1995 85 757 764
40. V illunger A E gle A M arschitz I K os M B ock G L udwig H G eley S K ofler R G reil R Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance Blood 1997 90 12 20
41. Z oi -T oli O M eijer CJ O udejans JJ de V ries E van B eek P W illemze R Expression of Fas and Fas ligand in cutaneous B-cell lymphomas J Pathol 1999 189 533 538
42. X erri L D evilard E H assoun J H addad P B irg F Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis Leukemia 1997 11 1868 1877
43. G ronbaek K S traten PT R alfkiaer E A hrenkiel V A ndersen MK H ansen NE Z euthen J H ou -J ensen K G uldberg P Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity Blood 1998 92 3018 3024
44. E ischen CM K ottke TJ M artins LM B asi GS T ung JS E arnshaw WC L eibson PJ K aufmann SH Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions Blood 1997 90 935 943
45. W ieder T E ssmann F P rokop A S chmelz K S chulze -O sthoff K B eyaert R D orken B D aniel PT Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3 Blood 2001 97 1378 1387
46. S chattner EJ E lkon KB Y oo DH T umang J K rammer PH C row MK F riedman SM CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway J Exp Med 1995 182 1557 1565
47. W ang D F reeman GJ L evine H R itz J R obertson MJ Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies Br J Haematol 1997 97 409 417
48. X erri L B ouabdallah R D evilard E H assoun J S toppa AM B irg F Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation Br J Cancer 1998 78 225 232